Joe-Elie Salem1, Marie Bretagne2, Benedicte Lebrun-Vignes2, Xavier Waintraub3, Estelle Gandjbakhch3, Francoise Hidden-Lucet3, Paul Gougis2, Anne Bachelot4, Christian Funck-Brentano2. 1. Inserm, UNICO-GRECO Cardio-Oncology Programme, Department of Pharmacology, CIC-1421, Pharmacovigilance Unit, Pitié-Salpêtrière Hospital, Sorbonne Université, AP-HP, 75013 Paris, France; Pharmacology and Cardio-Oncology Program, Departments of Medicine, Vanderbilt University Medical Center, 37232 Nashville, TN, USA. Electronic address: joe-elie.salem@aphp.fr. 2. Inserm, UNICO-GRECO Cardio-Oncology Programme, Department of Pharmacology, CIC-1421, Pharmacovigilance Unit, Pitié-Salpêtrière Hospital, Sorbonne Université, AP-HP, 75013 Paris, France. 3. Inserm, ICAN, Rythmology Unit, Department of Cardiology, Pitié-Salpêtrière Hospital, Sorbonne Université, AP-HP, 75013 Paris, France. 4. Department of Endocrinology and Reproductive Medicine, IE3M, centre de référence des maladies endocriniennes rares de la croissance et centre des pathologies gynécologiques rares, ICAN, Pitié-Salpêtrière Hospital, AP-HP, 75013 Paris, France.
Abstract
BACKGROUND: Long QT syndrome (LQTS) can cause the potentially fatal ventricular tachycardia torsades de pointes (TdP). QT interval corrected for heart rate (QTc) is shorter in men than in women, with testosterone contributing to shorten QTc. We recently described male hypogonadism as a reversible risk factor for acquired LQTS and TdP, but the clinical characteristics of such patients have not been characterized. AIMS: To describe the clinical characteristics of men with acquired LQTS or TdP associated with hypogonadism caused by endocrine conditions or androgen deprivation therapy (ADT), and to evaluate the relationship between testosterone concentrations and electrocardiographic changes. METHODS: We searched MEDLINE (to 04 January 2019) and the French pharmacovigilance database (to 09 August 2018) to identify male cases of acquired LQTS and TdP associated with endocrine hypogonadism or ADT; their narratives were gathered from reporting collaborators. RESULTS: We identified seven cases of TdP (one fatal) with endocrine hypogonadism, abnormally long QTc and morphologically abnormal T-wave notches. After reversion of low testosterone concentrations in the surviving patients (N=6), QTc shortened, T-wave morphology normalized and there was no TdP recurrence. Among these cases, none had mutation in the LQTS genes, three men required testosterone and three had reversible hypogonadism after resolution of a concurrent acute severe illness. We found an additional 27 reports of men with LQTS (N=6), TdP (N=9; 2/9 fatal) or sudden death (N=12; 10/12 fatal) suspected to be induced or favoured by ADT (24/27 for prostate cancer). Generally, after ADT withdrawal, QTc shortened and no TdP recurred. CONCLUSION: We propose seeking for hypogonadism caused by endocrine conditions or ADT in men presenting with TdP. Caution is warranted when ADT is used in situations at risk of TdP. Testosterone may be useful to treat or prevent TdP.
BACKGROUND:Long QT syndrome (LQTS) can cause the potentially fatal ventricular tachycardia torsades de pointes (TdP). QT interval corrected for heart rate (QTc) is shorter in men than in women, with testosterone contributing to shorten QTc. We recently described male hypogonadism as a reversible risk factor for acquired LQTS and TdP, but the clinical characteristics of such patients have not been characterized. AIMS: To describe the clinical characteristics of men with acquired LQTS or TdP associated with hypogonadism caused by endocrine conditions or androgen deprivation therapy (ADT), and to evaluate the relationship between testosterone concentrations and electrocardiographic changes. METHODS: We searched MEDLINE (to 04 January 2019) and the French pharmacovigilance database (to 09 August 2018) to identify male cases of acquired LQTS and TdP associated with endocrine hypogonadism or ADT; their narratives were gathered from reporting collaborators. RESULTS: We identified seven cases of TdP (one fatal) with endocrine hypogonadism, abnormally long QTc and morphologically abnormal T-wave notches. After reversion of low testosterone concentrations in the surviving patients (N=6), QTc shortened, T-wave morphology normalized and there was no TdP recurrence. Among these cases, none had mutation in the LQTS genes, three men required testosterone and three had reversible hypogonadism after resolution of a concurrent acute severe illness. We found an additional 27 reports of men with LQTS (N=6), TdP (N=9; 2/9 fatal) or sudden death (N=12; 10/12 fatal) suspected to be induced or favoured by ADT (24/27 for prostate cancer). Generally, after ADT withdrawal, QTc shortened and no TdP recurred. CONCLUSION: We propose seeking for hypogonadism caused by endocrine conditions or ADT in men presenting with TdP. Caution is warranted when ADT is used in situations at risk of TdP. Testosterone may be useful to treat or prevent TdP.
Authors: P G Hiremath; F Bhondoekhan; S A Haberlen; H Ashikaga; F J Palella; G D'Souza; M J Budoff; L A Kingsley; A S Dobs; W S Post; E Z Soliman; T T Brown; K C Wu Journal: HIV Med Date: 2020-12-03 Impact factor: 3.180
Authors: Virginie Grouthier; Melissa Y Y Moey; Estelle Gandjbakhch; Xavier Waintraub; Christian Funck-Brentano; Anne Bachelot; Joe-Elie Salem Journal: Int J Mol Sci Date: 2021-02-02 Impact factor: 5.923
Authors: Andrei Cristian Dan Gheorghe; Ana Ciobanu; Andreea Simona Hodorogea; George Daniel Radavoi; Viorel Jinga; Ioan Tiberiu Nanea; Gabriela Silvia Gheorghe Journal: Cardiovasc Toxicol Date: 2020-08 Impact factor: 3.231